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INTRODUCTION
According to WHO, currently 215 countries/areas/territories report a total of more than 176
million confirmed COVID-19 cases and 3.8 million deaths (June 18, 2021). SARS-CoV-2, the
causative agent of COVID-19, does not impact only the respiratory system but also the various
organs in the body. It can directly or indirectly affect the pulmonary system, cardiovascular system
(including heart failure), renal system (including kidney failure), hepatic system (including liver
failure), gastrointestinal system, nervous system, and/or various systems, leading to shock and
multi-organ failure (Zaim et al., 2020). In consequence, comorbidity in these systems leads to a
higher risk for a severe disease progression.
POST-ACUTE/CHRONIC COVID-19
In 2003, there was an outbreak of SARS-CoV-1, and follow-up data showed that, after several
years, in about 40% of the patients, long-term/chronic symptoms persisted, for example,
psychiatric illness (post-traumatic stress syndrome, depression, somatoform pain disorder, and
panic disorder), chronic fatigue, and reduced pulmonary function (Lam, 2009; Ngai et al., 2010).
Recently, similar trends of long-term symptoms have been reported for patients infected with
SARS-CoV-2. The definition is still evolving as is the name, for example, long COVID-19,
COVID-19 long hauler, post-COVID-19, post-acute COVID-19, and chronic COVID-19 are used
to describe symptoms from patients with acute COVID-19 that last longer than 4 or 12 weeks
and are not attributable to alternative diagnoses. The studies investigating this phenomenon
vary in their methods, spanning from simple questionnaire or telephone interviews to physical
examination, chest scan, and blood markers. Further varying parameters are the inclusion criteria,
the timing of questioning/examination after recovery, age, and severity of cases. Many studies also
have a rather small number of participants and therefore need to be looked at with some caution.
Despite these limitations, all studies that we are aware of point in one direction: a large percentage
of patients, according to a meta-analysis including 47,910 patients, about 80%, developed at least
one chronic symptom (Lopez-Leon et al., 2021).
A recent study from China looked at the health status of 1,733 COVID-19 patients (age 47–65
years) 6 months after their discharge from the hospital. They were interviewed with a series of
questionnaires for evaluation of symptoms and health-related quality of life; they also underwent
physical examination and a 6-min walking test and received blood tests (Huang et al., 2021).
From these patients, 76% showed at least one symptom that did not resolve in 6 months. The
main symptoms were fatigue and/or muscle weakness (63%), sleep disturbance (26%), dyspnea
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(23%), anxiety/depression (23%), hair loss (22%), loss of
test/smell (7–11%), chest pain (5%), and diarrhea (5%). Patients
who had more severe symptoms during their hospital stay
had consequently more severe impaired pulmonary diffusion
capacities and abnormal chest imaging manifestations. Several
smaller-scale studies in France (Garrigues, 2020; Carvalho-
Schneider, 2021), UK (Arnold et al., 2021; Halpin, 2021),
Italy (Carfì et al., 2020), Spain (Moreno-Pérez et al., 2021),
Mediterranean (Moreno-Pérez et al., 2021), and USA (Chopra
et al., 2021) showed similar results [for an overview, see
Nalbandian et al. (2021)]. In these studies, between 32.6 and
87.4% of the patients reported that at least one symptom
had not resolved after COVID-19. The main symptoms were
fatigue (34.8–64%), joint pain (4.5–27.3%), sleep disturbance
(24–30.8%), dyspnea (11.1–43.4%), loss of taste/smell (10.8–
21.7%), cough (2.1–21.3%), headache (1.8–17.8%) hair loss
(20%), chest pain (10.8–21.7%), and diarrhea (0.9–10.5%). A
meta-analysis including 47,910 patients followed up at 14 to
110 days post-COVID-19 showed that they present very similar
results: 80% (95% confidence interval, CI: 65–92%) of the
patients developed one or more long-term symptoms. The
most common symptoms were fatigue (58%), headache (44%),
attention disorder (27%), hair loss (25%), and dyspnea (24%)
(Lopez-Leon et al., 2021). Moreno-Pérez et al. showed in a study
with a systematic assessment 10–14 weeks after disease onset
of 277 patients (age 42–67.5 years, 65.7% with severe illness)
that at least one chronic COVID-19 symptom was detected
in 50.9%. Importantly, for the patients experiencing a chronic
COVID-19 symptom, the life quality deteriorated by a median
of nine points according to the EuroQol Visual Analog Scale
(Moreno-Pérez et al., 2021).
We believe that it is urgent to define a term describing
these symptoms with a clear indication of time after onset of
diseases and method of diagnosis, for example, chronic COVID-
19 syndrome (CCS), in order to perform more comparable
systematic studies not only to gain understanding of the
underlying causes but also to develop targeted therapies. In our
opinion, important are studies that follow patient groups (severe,
hospitalized but not severe, and mild) with a range of diagnostic
procedures in order to understand the progression and regression
of symptoms. For more than 170million confirmed cases plus the
unconfirmed cases, a high percentage will face CCS, and despite
most of them being categorized as mild in medical terms, fatigue,
joint pain, headache, anxiety, depression, and dyspnea will lead
to a reduced quality of life. Providing curative solutions, not
symptom management, should be the aim of further research in
this area.
SARS-CoV-2 AND THE HUMAN GUT
The gastrointestinal system is vulnerable to infections with
SARS-CoV-2. SARS-CoV-2 requires angiotensin I-converting
enzyme 2 (ACE2) as a receptor to enter a human cell.
In addition, host proteases are required to prime the spike
protein, especially transmembrane serine protease 2 (TMPRSS2)
(Hoffmann et al., 2020). Hikmet et al. showed that the expression
of ACE2, as determined by transcriptomics by three different
independent consortia, is very high in the small intestine,
120 consensus normalized expression units (NX), and in the
colon and duodenum, both about 50 NX, compared to 0.8
NX in the lung (Hikmet et al., 2020). The data was supported
by immunohistochemistry on human tissue, showing the high
expression of ACE2 protein in the enterocytes and crypt cell of
the duodenum and small intestine and in the enterocytes of the
colon. The expression in the lung was also minimal (Hikmet
et al., 2020). Using RNAseq, the expression of TMPRSS2 was
determined to be high in the small intestine, colon, stomach,
and esophagus; however, it was also high in the lungs (TMPRSS2
Gene—GeneCards | TMPS2 Protein | TMPS2 Antibody). The co-
expression of ACE2 and TMPRSS2 in esophageal upper epithelial
cells, glandular cells, and cells from the ileum and colon was
confirmed by single-cell transcriptomic analysis (Zhang et al.,
2020). Because of the independent methods, the data is very
robust, and the digestive tract, based on the receptor and the
protease levels, is an “ideal” place for SARS-CoV-2 infection
to occur. It is therefore rather surprising that, according to a
meta-analysis comprising 4,243 patients, only 17.6% (95% CI:
12.3–24.5%) had a prevalence of any gastrointestinal symptom.
However, SARS-CoV-2 RNA could be detected in either anal
swabs or stool specimens in 29–80% of the tested patients
(Cheung et al., 2020). It seems that infection in the gut occurs
in a large percentage of patients, but the development of gastro-
intestinal symptoms is less frequent.
SARS-CoV-2 AND THE HUMAN GUT
MICROBIOME
The first pilot studies with small numbers of COVID-19 patients
have found an altered microbiome compared to healthy controls
(Gu et al., 2020; Zuo et al., 2020a,b; Chen et al., 2021; Yeoh
et al., 2021; Zuo et al., 2021). These changes are also different
from the changes seen in patients that were infected with the
flu strain H1N1. There are limitations of these studies in terms
of representation of age, sex, illness severities, comorbidities,
ethnicities, diverse patient treatment (especially antibiotic
treatment), severity of immune reaction during illness, diet,
and heterogeneity of microbiome across the population. In
our opinion, there is an urgent need to study the effect of
SARS-CoV-2 on the human microbiome, especially the long-
term effects, in larger trials and in more depth. However,
besides these limitations, all studies reported a significant
decrease in diversity and abundance and consequently an
enrichment of opportunistic pathogens, also independently
of antibiotic treatment—for example, one study showed the
increased relative abundance of opportunistic pathogens
like Streptococcus and Rothia (Gu et al., 2020). In a pilot
study, Zuo et al. investigated the changes of the human gut
microbiota during the time of hospitalization (Zuo et al.,
2020b). Compared to healthy individuals, where Eubacterium,
Faecalibacterium prausnitzii, Roseburia, and Lachnospiraceae
taxa are prevalent, the gut microbiome of patients with
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COVID-19 showed an enrichment of opportunistic pathogens—
for example, Clostridium hathewayi, Bacteroides nordii, and
Actinomyces viscosus—and, at the same time, depletion of
commensals. These changes occurred for both patients that
did and did not receive antibiotics. Most importantly, gut
dysbiosis persists during the COVID-19 disease course,
even after clearance/recovery from SARS-CoV-2 infection.
The baseline fecal abundance of the bacteria Coprobacillus,
Clostridium ramosum, and Clostridium hathewayi showed a
strong correlation with COVID-19 disease severity. In contrast,
Alistipes onderdonkii and Faecalibacterium prausnitzii, the
later known to have an anti-inflammatory activity, showed an
inverse correlation.
In another small study, Zuo et al. demonstrated that SARS-
CoV-2 replication occurs even without any gastrointestinal
symptoms (Zuo et al., 2021). This study confirmed that COVID-
19 patients showed an enrichment of opportunistic pathogens
coupled with a loss of salutary bacteria. In this study, the
authors reported that fecal samples with high SARS-CoV-2
infectivity had higher abundances of bacterial species Collinsella
aerofaciens, Collinsella tanakaei, Streptococcus infantis, and
Morganella morganii. Functional profiling revealed that these
bacteria increase the capacity for biosynthesis of nucleotide
and amino acid and carbohydrate metabolism (glycolysis). In
contrast, fecal samples with signature of low to no SARS-CoV-
2 infectivity had a higher abundance of Parabacteroides merdae,
Bacteroides stercoris, Alistipes onderdonkii, and Lachnospiraceae
bacterium 1_1_57FAA. Functional profiling revealed increases in
the capability to produce short-chain fatty acids.
Gou et al. have discovered blood proteomic biomarkers
that can predict the severity of COVID-19 (Gou et al.,
2020). Gut microbial features like the relative abundance
of Bacteroides genus, Streptococcus genus, Lactobacillus
genus, Ruminococcaceae family, Lachnospiraceae family,
and Clostridiales order will drive these biomarkers. The
fecal metabolome was investigated and showed that 45
fecal metabolites, mainly within the categories of amino
acids, fatty acids, and bile acids, can provide a link between
the identified core gut microbiota, inflammation, and
COVID-19 susceptibility.
The human gut mycobiome has also shown to be
influenced by infection with SARS-CoV-2 (Zuo et al.,
2020a). Hospitalized COVID-19 patients show a more
heterogeneous mycobiome than the healthy control
group. That indicates a transition into a more unstable
microbial community. Patients had increased proportions
of opportunistic fungal pathogens—Candida albicans,
Candida auris, and Aspergillus flavus—compared with
the controls.
A study with 70 hospitalized COVID-19 patients, where
28 got a multi-strain probiotic, showed a clear evidence of
benefit for the patients (d’Ettorre et al., 2020). All patients
who received the probiotic showed a higher reduction in
diarrhea and other symptoms and also an eightfold lower risk
in developing respiratory failure, a lower prevalence to be
transferred to ICU, and a lower mortality rate. A similar study
comprising 200 patients with severe COVID-19 pneumonia,
where 88 got an additional multi-strain probiotic, also showed
19% reduced mortality in the probiotic-treated group (Ceccarelli
et al., 2021).
IS THERE A CONNECTION BETWEEN
CHRONIC COVID-19 SYNDROME AND
CHANGES IN HUMAN GUT MICROBIOME?
There is evidence from several studies that SARS-CoV-2 infection
leads to changes in the microbiome. These changes can be
caused by an infection directly in the gut, as a response to
increased inflammation and crosstalk between the oral, lung,
and gut microbiome. In case a dysbiosis in the microbiome is
established, it can lead to or fuel inflammation, increase intestinal
permeability, and change the balance of signaling metabolites.
In addition, there is a complex interplay of gene expression
regulation via miRNA produced by the host, microbiomes, and
SARS-CoV-2 (Hong and Kim, 2021; Omer and Kubra, 2021).
We observed that some of the symptoms described in CCS,
like fatigue, sleep disturbance, joint pain, anxiety/depression,
headache, and diarrhea, have also been correlated with a dysbiosis
of the gut microbiome (Galland, 2014; Poroyko et al., 2016;
Molina-Torres et al., 2019; Peirce and Alviña, 2019; Smith et al.,
2019; Arzani et al., 2020; Matenchuk et al., 2020; Ogawa et al.,
2020). In our opinion, the similarities of symptoms are very
high, and given the fact that dysbiosis has been shown as a
consequence of SARS-CoV-2 infection, a connection between
CSS and dysbiosis of the microbiome should be considered for
further research despite the fact that there is no direct evidence
for this link yet. There are, however, initial positive effects by
using probiotics on acute COVID-19.
Here we postulate that, in a subset of patients, long-term
changes (dysbiosis) in the gut microbiota might drive or
support some symptoms, especially fatigue, joint pain, diarrhea,
headache, depression, and anxiety, as seen in chronic COVID-
19 syndrome. Dysbiosis in the gut microbiome can influence the
immune system, lung, and brain via the gut–lung axis and gut–
brain axis as well as other organs via miRNA and metabolites
produced by the microbiome. The gastrointestinal tract has not
just a digestive function but also is responsible for achieving
an immune system homeostasis. Yeoh et al. pointed out that
dysbiosis seen in COVID-19 patients drives inflammation and
fuels long-term symptoms (Yeoh et al., 2021). More research
needs to be done to investigate this possible correlation between
gut microbiome and CSS. In case such a correlation can be
found in a subgroup of patients, treatment can be initiated
by nutritional changes, pre- and probiotic supplements, or
fecal transplants.
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